Your patients are unique

Their treatment should be, too

Tempus’ advanced genomic testing

Superior Clinical Utility

Tempus’ advanced genomic testing

Superior Clinical Utility

Tempus provides unmatched clinical utility by combining cutting-edge technologies, ensuring the most accurate and actionable insights for patient care.

Identify

Therapies with high success likelihood

Determine

Ineffective drug treatments before administration

Identify

Therapies you may not have already considered

Match

Patient care planning to appropriate clinical trials

Tempus’ advanced genomic testing

Superior Clinical Utility

Tempus provides unmatched clinical utility by combining cutting-edge technologies, ensuring the most accurate and actionable insights for patient care.

Identify

Therapies with high success likelihood

Determine

Ineffective drug treatments before administration

Identify

Therapies you may not have already considered

Match

Patient care planning to appropriate clinical trials

Advancing cutting-edge genomic testing

Tempus delivers superior clinical utility through a combination of advanced genomic technologies that set it apart from the competition.

Eliminate false positives in somatic variant calling

Correct underrepresented populations in genomic databases

Identify somatic mutations in non-white patients accurately

Improve targeted therapies for non-white patients

Reduce inflated TMB values to prevent misuse of CPI

Report germline variants for cancer biology insights

Enable early cancer diagnosis for at-risk family members

Incorporate germline testing into screening programs

  1. By sequencing both tumour and normal tissue, Tempus eliminates false positives in somatic variant calling, providing highly accurate results. This approach eliminates the chance of misidentifying inherited variants as somatic mutations, which significantly improves the precision of treatment recommendations​.1,2,3
  2. In addition, this approach reduces the falsely classified variants in non-White populations due to underrepresentation in population databases4, and corrects TMB values across all racial groups, with a pronounced correction in Black and Asian populations5,6. This reduction in inflated TMB values helps avoid inappropriate use of therapies like checkpoint inhibitors (CPI), which may not be effective for patients with inaccurately high TMB values based on tumour-only sequencing.
  3. By using matched-normal sequencing, non-White patients may experience improved therapeutic outcomes by ensuring that somatic mutations are accurately identified and not confounded by inherited variants. This improves the precision of targeted therapies and reduces the likelihood of inappropriate treatment decisions​7.
  4. Because Tempus sequences the tumour and the normal tissue, potential germline variants are also identified and reported, which gives valuable insight into the biology of the cancer. This not only informs treatment decisions but also provides an opportunity for specific germline testing for at risk family members to support a proactive approach to early cancer diagnosis and incorporation into appropriate screening programs.8

Improve gene fusion detection with RNA and DNA (29% increase with RNA sequencing

Ensure critical treatment opportunities aren't missed by capturing key gene fusions that drive tumour growth.

Tempus uses both DNA and RNA sequencing to capture actionable gene fusions that DNA-only sequencing may miss. A study involving over 84,000 patients demonstrated a 29% increase in clinically actionable fusion detection when RNA sequencing was added to DNA sequencing​.9,10 This combination ensures that critical treatment opportunities, such as gene fusions driving tumour growth, are not overlooked​.11

Identify non-overlapping actionable variants

Increase detection of clinically significant variants

Comprehensive tumour genetic profiling

Enhance treatment decision-making

Tempus enables concurrent tissue and liquid biopsy testing, identifying non-overlapping actionable variants across both modalities. Research has shown that up to 15% of patients with metastatic cancers have clinically significant variants found in liquid biopsy that were not detected in tissue samples, offering a more comprehensive view of the tumour’s genetic profile.12,13,14

Approach long-term disease management better

Track genomic changes across disease stages

Detect actionable mutations post-treatment

Optimise therapeutic interventions

Address tumour heterogeneity

By tracking genomic changes across different stages of the disease, Tempus helps clinicians personalise treatment regimens and improve patient outcomes. Studies demonstrate that longitudinal sequencing enhances the detection of actionable mutations that may arise post-treatment, providing a more dynamic and adaptive approach to cancer care. This makes it possible to optimise therapeutic interventions and address tumour heterogeneity, ultimately leading to better long-term disease management.15,16,17

Integrating multimodal data

Tempus combines genomic, clinical, and imaging data to give you an accurate view of each patient’s cancer, empowering more informed treatment decisions.

Identify actionable mutations and fusions that inform targeted treatment options

Attain more context to complement genomic data by understanding tumour morphology and progression

Leverage language processing (NLP) and AI algorithms to analyse patient histories, clinical notes, and EHR data

Next-generation sequencing (NGS)

Tempus sequences both DNA and RNA in addition to certain IHC testing to identify actionable mutations and fusions that inform targeted treatment options.

Pathology and radiology data

By integrating pathology and radiology results, Tempus enhances the understanding of tumour morphology and progression, giving physicians more context to complement genomic data.

Clinical notes and electronic health records (EHR)

Tempus uses natural language processing (NLP) and AI algorithms to analyse patient histories, clinical notes, and EHR data, ensuring that relevant clinical information is taken into account alongside molecular findings.

Artificial Intelligence (AI)

Tempus employs AI and machine learning models to process and interpret vast amounts of data, providing physicians with real-time insights, such as therapy recommendations and clinical trial matching, based on the patient’s unique molecular and clinical profile.

Moving toward a multimodal approach

Integrating diverse data sources, helping you make better decisions
This multimodal approach allows Tempus to offer a more accurate and personalised treatment recommendation by integrating diverse data sources. It helps you make better-informed decisions to optimise patient outcomes.

Seamless ordering & reporting

Tempus makes genomic testing easy with streamlined test ordering, tracking, and reporting through an intuitive digital platform.

Access reports, track test status, and receive notifications from any device

An intuitive digital portal that centralises all aspects of test management

Highly personalised ordering service tailored to your needs

Attain the highest level of treatment confidence today

Optimise patient outcomes through advanced genomic insights
Together, these innovations give you the highest confidence level in your treatment decisions, optimising patient outcomes by offering insights that other platforms may miss.

Contact us to learn more

Leigh Leppan
Head of Customer Service

Connect with us

UK office

South Africa office
Website's carbon footprint
We are committed to responsible business practices, championing SDGs in every facet of our work to achieve net-zero targets.

Bespoke customer service

At LINK Medical, we provide a highly personalised ordering service tailored to each physician’s needs. Our team manages the entire process, from sourcing the FFPE block from pathology and coordinating with labs to ensure rapid specimen shipment to arranging blood or saliva samples directly with the patient. We also support with all necessary documentation, registering the order with Tempus on behalf of the physician, and follow-up daily to address any queries promptly. Once the report is finalised, we notify the physician immediately and arrange a direct consultation with Medical Affairs to discuss any questions related to the patient’s report. This bespoke service allows physicians to focus on patient care while we manage the logistical details, providing a smooth and efficient experience.

Tempus HUB

An intuitive digital portal that centralises all aspects of test management. The platform allows for real-time tracking of test progress, allowing healthcare providers to monitor the status of patient samples and reports in real time. The platform allows for seamless integration of clinical notes, pathology results, and other relevant data, ensuring that the genomic reports are comprehensive and contextually relevant to each patient’s unique medical history.

Automated actionable insights

Once the test results are available, Tempus generates detailed yet easily interpretable reports. These reports highlight actionable mutations, potential therapeutic options, and relevant clinical trials. With a typical turnaround time of 7-10 days from sample receipt, physicians receive timely insights to support urgent decision-making. In addition to traditional PDF reports, Tempus Hub delivers additional AI-powered insights directly to physicians, harnessing the power of data from thousands of molecularly similar patient cases.

Mobile accessibility

With the Tempus mobile app, physicians can access reports, track test status, and receive notifications from anywhere, allowing for greater flexibility and real-time updates on the go. Tempus One makes accessing your patient's data so much easier with instant access to patient-specific genomic insights, therapy recommendations, and clinical trial options, allowing for data-driven decision-making at the point of care.